Durable complete response to PET‐CT driven stereotactic radiation therapy plus pembrolizumab for pleomorphic Pancoast cancer: Case report and literature review

Abstract

Key Clinical Message PET‐driven SBRT plus pembrolizumab as first‐line therapy against pleomorphic Pancoast cancer appears beneficial, probably due to high equivalent doses of SBRT on photopenic necrotic core and synergic immune system stimulation of immunoradiotherapy.

Keywords

• image‐guided radiation therapy
• immune checkpoint inhibitors
• Pancoast tumor
• pleomorphic lung cancer
• radioimmunotherapy
• stereotactic body radiotherapy